ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, today announced that Zhen Li, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the UBS Global Biopharma Conference in London, UK on Monday, November 16, at 2:00 p.m. GMT.
A live webcast will be available on the Events page of ADARx’s investor website. A replay of the conference webcast will be archived on the company's website for 90 days.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and our two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond our named programs, we plan to continue to leverage our proprietary technologies to strategically expand our pipeline of next-generation siRNA therapeutics. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.
Contacts Investors: ir@adarx.com Media: teri@redhousecomms.com
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Growth Stocks to Buy While They’re Still Undervalued
3 of the Best Core Stocks to Own
3 Great New ETFs From 2026
The 10 Best Companies to Invest in Now
United States